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size, concentric LVH, no family history of LVH, 
or at least 2 ‑mm regression of the wall thickness 
after detraining.
As for pathological causes, the most common 
pathomechanism of LVH is a long ‑term increase 
in afterload, as observed in hypertension or aor‑
tic stenosis. Untreated or poorly controlled hy‑
pertension results in mild ‑to ‑moderate LVH (usu‑
ally <15 mm) and is frequently accompanied by 
other features, such as history of hypertension 
or evidence of other end ‑organ damage.3 Mod‑
erate concentric LVH is present in the majori‑
ty of patients with degenerative aortic stenosis.4 
Less commonly, LVH results from volume over‑
load states, such as in aortic and mitral regur‑
gitation, dilated or restrictive cardiomyopathy, 
heart failure, ventricular septal defect, and aor‑
tic coarctation.5-7
Another relatively common condition that 
is always associated with LVH is HCM. In fact, 
HCM is not a rare condition as its prevalence 
can vary between 0.2% (1 of 500 people/popu‑
lation) and 0.5% (1 of 200 people/population), 
which makes it the most widespread cardiomy‑
opathy.8 To be definitive on the nature of HCM 
and the terminology used here, it should be clear‑
ly stated that HCM is a genetic disease caused by 
mutations in cardiac sarcomere protein genes, 
whereas all other conditions that phenotypical‑
ly mimic HCM are not HCM as such but are in‑
stead termed phenocopies.9 
Hypertrophic cardiomyopathy is inherited in 
an autosomal dominant pattern with variable 
expressivity and age ‑related penetrance. So far, 
more than 1500 (often private) mutations in 11 
genes that encode thick or thin myofilament pro‑
teins of the sarcomere have been associated with 
HCM. These mutations result in hypertrophied 
and disorganized cardiomyocytes. Hypertrophic 
cardiomyopathy is characterized by LVH of vari‑
ous degrees, morphologies, and patterns: LV wall 
thickness exceeding 15 mm in any myocardial seg‑
ment and asymmetric septal hypertrophy (the ra‑
tio of septal to posterior wall thickness >1.3 for 
normotensive individuals or >1.5 for hypertensive 
patients) are all considered diagnostic for HCM. 
The interventricular septum is typically affect‑
ed, and its morphology may vary from reverse 
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is common in patients with cardiovascular dis‑
ease, in those with cardiovascular risk factors, 
and in healthy individuals. Although electro‑
cardiography is a first ‑line diagnostic modali‑
ty, echocardiography is highly recommended to 
confirm the diagnosis. According to recent guide‑
lines, LVH is defined as an increase of left ven‑
tricular (LV) mass, with the cutoff value of more 
than 150 g (>90 g/m2) for women and more than 
200 g (>103 g/m2) for men. In addition, septal 
and posterior wall thickness should exceed 9 mm 
and 10 mm for women and men, respectively.1 
At the microscopic level, LVH is characterized 
by an increase in the size or number of sarco‑
meres (or both).
Although common, LVH should not be re‑
garded as an insignificant marker of disease. 
On the contrary, a thorough diagnostic workup 
should be performed once it is detected. A mere 
simplification by connecting LVH with hyperten‑
sion may result in the underdiagnosis of a sub‑
stantial number of patients and, consequent‑
ly, may lead to ineffective and even detrimental 
therapy. Since it is highly impractical to simply 
list the multiple conditions that may be associ‑
ated with LVH, what is needed is a comprehen‑
sive LVH diagnostic algorithm as a way to facil‑
itate a differential diagnosis. In line with this, 
a simplified 3 ‑stage workup has been developed 
(FIGURE 1). In brief, the physiologic causes of LVH 
should be considered first, followed by the most 
common conditions that cause LVH. Hypertrophic 
cardiomyopathy (HCM) is a natural consequence 
of LVH; however, other rare causes of LVH are also 
possible. A detailed description of the numerous 
conditions leading to LVH is beyond the scope 
of this paper; nevertheless, certain useful point‑
ers and red flags were briefly highlighted below.
Generally, the cause of LVH nay be either phys‑
iologic or pathological. The physiologic causes oc‑
cur in 3 distinct groups of people: athletes, over‑
weight or obese individuals, and pregnant wom‑
en.2 Typically, highly ‑trained athletes may de‑
velop LVH, known as the “athlete’s heart,” but 
apart from a history of long ‑term training, the fol‑
lowing red flags should be considered: a mod‑
erate LVH of 13 to 15 mm, increased LV cavity 
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coagulation disorders, and the end ‑stage phase 
of HCM, which leads to heart failure.10-12
Finally, in approximately 5% to 10% of pa‑
tients with LVH, who would otherwise be di‑
agnosed with HCM, much rarer causes warrant 
further investigation. Unlike in HCM or hyper‑
tension, LVH in those rare conditions does not 
always result from cardiomyocyte hypertrophy 
but rather from intra‑ or extracellular depos‑
its. Among the storage diseases, glycogen and 
lysosomal diseases are most prominent. Gly‑
cogen diseases arise from inborn errors of gly‑
cogen metabolism leading to the accumulation 
of various glycogen byproducts. Deficiency in 
acid maltase (Pompe disease) and in lysosome‑
‑associated membrane protein 2 (Danon dis‑
ease) is known to cause severe LVH. Although 
the diagnosis of a glycogen storage disease is 
curvature, neutral, to sigmoid. Asymmetric LVH 
of the basal anterior septum is most common, fol‑
lowed by that of the anterior free wall and poste‑
rior septum; however, any localization, including 
concentric, mid ‑ventricular and apical, is possible. 
While most patients with HCM have no or just 
minimal symptoms, a substantial proportion of 
individuals (15%–20%) complain of a variety of 
symptoms, such as chest pain, palpitations, fa‑
tigue, dyspnea, and presyncopal states or synco‑
pe. These clinical manifestations result from var‑
ious pathologies that can often coexist, such as 
diastolic dysfunction, microvascular angina, LV 
outflow tract obstruction, supraventricular ar‑
rhythmias (most frequently atrial fibrillation) 
and ventricular arrhythmias (that may lead to 
sudden cardiac death), stroke as a result of atri‑
al fibrillation but also caused by intrinsic blood 
FIGURE 1  
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as Kearns–Sayre or MELAS syndromes, LVH is 
also a common feature. Red flags such as myop‑
athy (raised creatine kinase levels), deafness, vi‑
sual disturbances, hypotension, and metabol‑
ic acidosis (raised lactate levels) may aid the di‑
agnosis. Left ventricular hypertrophy can also 
be observed in neuromuscular disorders, such 
as Duchenne and Backer muscular dystrophies 
or Friedreich ataxia. These are severe neurologic 
conditions that usually lead to advanced physical 
disability and respiratory failure. However, due 
to progress in neurologic and pulmonary reha‑
bilitation, including the availability of home res‑
pirators, some of those patients gradually devel‑
op heart failure due to dilated or hypertrophied 
hearts. In some rare endocrine disorders, such as 
pheochromocytoma, acromegaly, or Conn syn‑
drome, LVH is a frequent symptom due to poor‑
ly controlled hypertension. Lastly, LVH may re‑
sult from drug toxicity, particularly with the use 
of anabolic steroids or tacrolimus.
It is not clear whether the list of potential fac‑
tors conducive to LVH is complete; nevertheless, 
a more focused approach, including the consid‑
eration of rare diseases, may help raise aware‑
ness of the numerous conditions that may man‑
ifest with LVH.
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definitely not straightforward, there are some 
signs that can be considered red flags, such as 
progressive myopathy accompanied by a high 
level of creatine kinase, hypotension, ophthal‑
mologic abnormalities, and variable intellectual 
disability. Currently, enzyme replacement ther‑
apy (ERT) is available only for Pompe disease. 
Among the lysosomal diseases, Fabry disease is 
an X ‑linked storage disease that is caused by de‑
ficient activity of the lysosomal enzyme alpha‑
‑galactosidase A, resulting in the accumulation 
of globotriaosylceramide in lysosomes in multi‑
ple cell types in the body. Patients present with 
peripheral neuropathy of the hands and feet, 
alimentary tract disorders (nausea, abdominal 
pain, diarrhea), progressive renal insufficiency, 
reduced sweating and the cutaneous lesions of 
angiokeratoma corporis, corneal deposits, and 
cerebrovascular involvement (transient isch‑
emic attack and stroke). As for cardiovascular 
manifestations, LVH, conduction disturbances 
(usually pacemakers are indicated), and hyper‑
tension are most often seen. The detection of 
low or no alpha ‑galactosidase activity is confir‑
matory for the diagnosis of Fabry disease. Es‑
tablishing the correct diagnosis is important 
since ERT therapy (agalsidase alfa and beta) has 
been shown to reduce LVH and ameliorate re‑
nal failure.13
Another group of diseases that are frequently 
associated with LVH are infiltrative diseases, in‑
cluding amyloidosis, sarcoidosis, and hemochro‑
matosis. Amyloidosis is a heterogeneous group of 
diseases characterized by the deposition of amy‑
loid fibrils. Until now, more than 30 different mis‑
folded and/or misassembled proteins have been 
shown to have the propensity to form these types 
of amyloid fibrils. However, the ones that are 
most cardiac relevant are immunoglobulin light 
chain (AL amyloidosis) and transthyretin (ATTR 
amyloidosis). The clinical course and survival in 
cardiac amyloidosis are extremely poor. The sur‑
vival is less than 2 years for AL amyloidosis and 
2 to 3 years for ATTR amyloidosis. The diagno‑
sis requires a multidisciplinary approach as well 
as the integration of various modalities such as 
99mTc ‑DPD scintigraphy, magnetic resonance im‑
aging, bone marrow or endomyocardial biopsy, 
and laboratory testing, including genetic studies. 
The diagnosis should not be delayed as specific 
therapies are available for AL amyloidosis: multi‑
drug chemotherapy and bone marrow transplan‑
tation, whereas for ATTR amyloidosis, there are 
a number of drugs available in clinical practice, 
including tafamidis, doxycycline, or patisiran.14,15
Rare multisystemic malformation syndromes, 
such as Noonan, Costello, LEOPARD, or Swyer, 
are also associated with LVH. In most instanc‑
es, the correct diagnosis is established in child‑
hood. Dysmorphic features, such as short stat‑
ure, hypertelorism, lower ear positioning, hy‑
permobility of the joints, chest deformation, and 
various degrees of mental retardation should 
raise suspicion. In mitochondrial diseases, such 
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